Patents

To obtain and maintain patents and other intellectual property (IP) rights that protect LIDDS’ technologies, methods and products is an important part of the company’s ability to create long-term values for shareholders.

LIDDS has received more than 130 national patents and a comprehensive patent protection has been established for the NanoZolid platform in all major markets. The patent portfolio is considered to be solid and covers, among other things, methods for controlling the release of drugs, manufacturing processes, equipment and aids for injection, methods and processes for controlling the rate of cure, and the principle for treating prostate cancer with NanoZolid-formulated drug.

• In 2021, LIDDS received a patent approval in India. This means that all of LIDDS’ original five patent families are approved in the countries in which LIDDS has chosen to protect the technology. The patent protection is thus available in Denmark, Finland, France, Germany, Hungary, Italy, the Netherlands, Poland, Spain, Sweden, Switzerland, Turkey. Great Britain, Ireland, Greece, Czech Republic, USA, Australia, Canada, China, Hong Kong, Japan, Mexico, Russia, South Africa Korea, Israel, South Africa, India, Hong Kong, Brazil and Singapore.
• The NanoZolid technology has approved process patents in EU and US, which provide patent protection until 2037 for LIDDS’ technology platform and for the drugs developed with NanoZolid.
• In January 2020, the United States Patent and Trademark Office approved a product patent covering all NanoZolid products. The patent’s specific focus on product provides protection regardless of whether the product is manufactured with a process developed by LIDDS or with another process that generates the same product. The patent is valid until 2037.
• In 2021, LIDDS received patent protection for its production process in Russia, Australia and China.

In addition to the patent protection for the NanoZolid technology that is valid until 2037, LIDDS has the option of obtaining a patent extension of an additional five years in Europe, provided that the drug substance is not regulatory approved. There is also the possibility of obtaining extended intellectual property protection in the United States.